Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Moderate Buy” by Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.6667.

Several research analysts have recently issued reports on NMRA shares. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Tuesday, April 21st. Finally, Guggenheim reiterated a “buy” rating and set a $14.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 31st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Siren L.L.C. lifted its position in Neumora Therapeutics by 35.1% during the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after purchasing an additional 2,209,039 shares during the period. Perceptive Advisors LLC bought a new position in Neumora Therapeutics in the first quarter worth approximately $9,953,000. Millennium Management LLC raised its position in Neumora Therapeutics by 80.1% in the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after acquiring an additional 1,608,266 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Neumora Therapeutics by 24.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock worth $2,588,000 after acquiring an additional 281,926 shares during the last quarter. Finally, Ikarian Capital LLC grew its position in shares of Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after acquiring an additional 1,265,910 shares during the period. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $1.60 on Thursday. The company has a quick ratio of 5.09, a current ratio of 5.09 and a debt-to-equity ratio of 0.75. The stock has a market cap of $296.45 million, a PE ratio of -1.20 and a beta of 2.73. The company’s fifty day moving average is $1.98 and its 200 day moving average is $2.26. Neumora Therapeutics has a 52 week low of $0.72 and a 52 week high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.02. Research analysts anticipate that Neumora Therapeutics will post -0.95 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.